AeroRx Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$20.8M
- Investors
-
4
AeroRx Therapeutics General Information
Description
Developer of combination drug therapies intended for respiratory disease treatment. The company develops treatments delivered via nebulization, focusing on older patients with chronic obstructive pulmonary disease, enabling patients to receive effective and targeted care.
Contact Information
Website
www.aerorxtx.comCorporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
Corporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
AeroRx Therapeutics Timeline
AeroRx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 07-Oct-2025 | $20.8M | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 30-Apr-2024 | Completed | Clinical Trials - Phase 2 |
AeroRx Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AeroRx Therapeutics Patents
AeroRx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024206662-A1 | Liquid formulations of indacaterol and glycopyrronium | Inactive | 30-Mar-2023 | ||
| EP-4499099-A1 | Liquid formulations of indacaterol and glycopyrronium | Pending | 30-Mar-2022 | ||
| EP-4499099-A4 | Liquid formulations of indacaterol and glycopyrronium | Pending | 30-Mar-2022 | ||
| US-20250177372-A1 | Liquid formulations of indacaterol and glycopyrronium | Pending | 30-Mar-2022 | ||
| WO-2023192445-A1 | Liquid formulations of indacaterol and glycopyrronium | Inactive | 30-Mar-2022 | A61K31/4704 |
AeroRx Therapeutics Signals
AeroRx Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Correlation Ventures | Venture Capital | Minority | ||
| Prebys Ventures | Impact Investing | Minority | ||
| Avalon Bioventures | Venture Capital | Minority |
AeroRx Therapeutics FAQs
-
When was AeroRx Therapeutics founded?
AeroRx Therapeutics was founded in 2022.
-
Where is AeroRx Therapeutics headquartered?
AeroRx Therapeutics is headquartered in La Jolla, CA.
-
What is the size of AeroRx Therapeutics?
AeroRx Therapeutics has 3 total employees.
-
What industry is AeroRx Therapeutics in?
AeroRx Therapeutics’s primary industry is Drug Discovery.
-
Is AeroRx Therapeutics a private or public company?
AeroRx Therapeutics is a Private company.
-
What is the current valuation of AeroRx Therapeutics?
The current valuation of AeroRx Therapeutics is .
-
What is AeroRx Therapeutics’s current revenue?
The current revenue for AeroRx Therapeutics is .
-
How much funding has AeroRx Therapeutics raised over time?
AeroRx Therapeutics has raised $26.8M.
-
Who are AeroRx Therapeutics’s investors?
Alexandria Venture Investments, Correlation Ventures, Prebys Ventures, and Avalon Bioventures have invested in AeroRx Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process